Intravenous injection of AAV-PHP.eB across the blood brain barrier in the adult mouse for central nervous system gene therapy

share:

Brief intro:

  • Author: Yongwei Shu, Jie Yao, Yang Qu, Jing Zheng, Jing Ding, Lina Zhang, Yefan Wang, Linlin Zhao, Jingyu Zhang, Siqi Tang
  • Journal: Oncology and Translational Medicine
  • Publication Date: 2019

Products/Services used in the paper

Quotation shows PackGene:Plasmid AAV-PHP.eB was purchased from PackGene Biotech, LLC.

Research Field:CNS

AAV Serotype:AAV-PHP.eB

Targeted organ:brain

Animal or cell line strain:8-week-old male C57BL mice with body weight of 250–300 g.

Request Quote

Abstract

Objective To verify the neurotypicality of AAV-PHP.eB after tail vein injection in adult mice and its efficiency in crossing the blood-brain barrier(BBB).Methods The rAAV-SYN-GFP plasmid was constructed, and adult C57 BL mice were injected with AAV PHP.eB: SYN-GFP in the tail vein(300 nL, virus titer 3 × 10~9 vg) and in the prefrontal lobe(50 L, virus tite5 × 10~(11) vg). The green fluorescent protein(GFP) signal in the brain was observed at two weeks, while the GFP signal in the peripheral organs was observed at four weeks. Results Two weeks after tail vein injection, GFP expression was observed throughout the brain especially in the cortex, hippocampus, and geniculate nucleus. No GFP signal was observed or detected by western blotting in the peripheral organs after four weeks. GFP signal was observed mainly at the loca site after prefrontal lobe injection.Conclusion AAV-PHP.eB: SYN-GFP can effectively cross the BBB in adult mice. Using a neuron-specific promoter allows exogenous gene expression in neurons; therefore, AAV-PHP.eB can be used as an effective carrier for studying diseases in the central nervous system(CNS).

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download